



PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 65783

Title: Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era

Reviewer's code: 03411775

Position: Editorial Board

Academic degree: FESC, MD, PhD

Professional title: Attending Doctor, Consultant Physician-Scientist

Reviewer's Country/Territory: Greece

Author's Country/Territory: United Kingdom

Manuscript submission date: 2021-03-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-09 08:58

Reviewer performed review: 2021-04-09 09:04

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors present a review on the duration of DAPT after PCI. This is a topic of clinical importance. There are some issues that have arisen as follows: **MAJOR COMMENTS** - The authors state that traditional DAPT duration is at least 12 months after drug-eluting stent implantation for low bleeding risk patients. However, this is misleading; according to the latest guidelines 12 months of DAPT is reserved only for acute coronary syndromes but not for chronic coronary syndromes (i.e. stable coronary artery disease). The standard duration of DAPT after elective PCI (with DES) is 6 months. The authors are also advised to review the latest ESC guidelines on chronic coronary syndromes. - Both the abstract and the initial part of the introduction refer to the duration of DAPT in general. However, according to the last sentence of the Introduction, the authors state that the review will investigate the shortened length of DAPT post stent implantation for acute coronary syndrome. The authors need to make clear in the abstract and earlier in the Introduction that the aim of the review is focused on DAPT for acute coronary syndromes. Also, the title should be modified accordingly. - The title/legend of Table 1 has problems regarding English syntax and is inadequate. The authors are advised to provide a concise Title and include notes as footnote below the table. Lastly, change "DAPT time" to "DAPT duration" - Table 1: do all these data refer to patients with acute coronary syndrome? - Shortened DAPT with newer generation DES/Evidence for shortened DAPT for specific stents: the authors need to clarify whether these results include patients with acute coronary syndrome or stable coronary artery disease - The 'Evidence for shortened DAPT for specific stents' is a very large section which is not easy for the reader. This section would benefit from better organization and subsections according to the duration of short DAPT regimen investigated. - Also, related to the previous comment, a figure (e.g. forrest plot) or Table



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

summarizing the main results for hard outcomes (death, MI, stent thrombosis) according to the duration of DAPT studied would be helpful for the reader - Lately, monotherapy with the newer P2Y12 inhibitors (e.g. ticagrelor) has been proposed and studied as a viable alternative. What do the authors think? - Personalized assessment of DAPT duration: Except for the PRECISE-DAPT score, are there any other scores used for determining the duration of DAPT? MINOR COMMENTS - There are no page numbers on the submitted documents - Pg. 7: what does "Cre8" stand for? - Pg.8: correct to "XIENCE Short DAPT Program" - Pg. 9 - Personalized assessment of DAPT duration - 2nd line: correct to "PRECISE-DAPT score" - English language Spelling: "implantion" -> "implantation" Pg 6: correct to "...that there were higher rates..." Pg 7: "...this was on an intention-to-treat analysis..." revise as needed Pg.7: correct to "...There appear to be some observational studies..." Pg.9 - Discussion - 1st sentence: Improve syntax Pg. 10: "As well as local effects to prevent stent thrombosis, ..." Improve wording; do not start with "as well as"